Status | Study |
Not yet recruiting |
Study Name: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant Condition: Post-transplant Lymphoproliferative Disease Transplant-Related Date: 2017-04-24 Interventions: Biological: Autologous EBV-CTL transduced with vector SFG-CNA12 |
Recruiting |
Study Name: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder Condition: Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder Monomorphic Post-Tra Date: 2016-09-06 Interventions: Biological: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes |
Recruiting |
Study Name: Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients Condition: Lymphoproliferative Disorders Date: 2015-07-15 Interventions: Other: Determining the source of EBV in severe EBV infections Blood units administered to patients with |
Recruiting |
Study Name: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy Condition: Posttransplant Lymphoproliferative Disorder Date: 2014-01-20 Interventions: Drug: Rituximab sc All patient |
Recruiting |
Study Name: Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Condition: Epstein Barr Virus Associated Non Hodgkin's Lymphoma Epstein Barr Virus Associated Hodgkin's Date: 2013-10-14 Interventions: Drug: Doxorubicin Doxorubicin |
Completed |
Study Name: Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Condition: Post-transplant Lymphoproliferative Disease (PTLD) Non Burkitt Date: 2010-03-11 Interventions: Drug: fludarabine, cyclophosphamide, doxorubicin, rituximab Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); C |
Active, not recruiting |
Study Name: Bortezomib Plus Rituximab for EBV+ PTLD Condition: Post-transplant Lymphoproliferative Disease Solid Organ Transpl Date: 2010-01-26 Interventions: Drug: bortezomib Given intrave |
Terminated |
Study Name: Relationship Between EBV and PTLD Condition: Pediatric Heart Transplant Date: 2005-09-20 |
Terminated |
Study Name: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Condition: Leukemia Lymphoma Lymphoproliferative Disorder Date: 2004-07-08 Interventions: Biological: beta-glucan Given |
Active, not recruiting |
Study Name: Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation Condition: Lymphoproliferative Disorder Date: 2003-08-06 Interventions: Biological: rituximab Cycles 1 |